Surrozen closes $95 million private‑placement tranche, extending cash runway to 2029
+1 new source since this summary was written
Surrozen Inc. completed the second and final tranche of its March 2025 private placement, raising roughly $95 million. The financing, issued on Oct 20 2026, included about 5.7 million common shares, pre‑funded warrants for 2.5 million shares and Series E warrants for 4.1 million shares. CEO Craig Parker said the proceeds give the company cash runway into 2029 and will fund the DUET Phase 1b/2a study of SZN‑8141 and the start of clinical work on SZN‑8143.
Why it matters
The company expects the new cash to support key ophthalmology trials through 2029, which should keep the pipeline on schedule and reduce financing risk for shareholders ().
Key facts
- 1The second tranche raised approximately $95 million (). stocktitan.net
- 2The second tranche raised $95.1 million (). tradingview.com
- 3The financing was closed on Oct 20 2026 (). stocktitan.net
- 4Surrozen issued about 5.7 million shares of common stock (). stocktitan.net
- 5Pre‑funded warrants exercisable for about 2.5 million shares were issued (). stocktitan.net
- 6Series E common stock warrants to purchase about 4.1 million shares were issued (). stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.